S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.59 (+2.41%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   255.02 (+2.66%)
TSLA   1,557.10 (+13.29%)
GE   6.72 (-0.15%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.10 (-1.80%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.52 (+0.79%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.59 (+2.41%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   255.02 (+2.66%)
TSLA   1,557.10 (+13.29%)
GE   6.72 (-0.15%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.10 (-1.80%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.52 (+0.79%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.59 (+2.41%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   255.02 (+2.66%)
TSLA   1,557.10 (+13.29%)
GE   6.72 (-0.15%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.10 (-1.80%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.52 (+0.79%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.59 (+2.41%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   255.02 (+2.66%)
TSLA   1,557.10 (+13.29%)
GE   6.72 (-0.15%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.10 (-1.80%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.52 (+0.79%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
Log in

NASDAQ:HOTHHoth Therapeutics Stock Price, Forecast & News

$2.65
-0.29 (-9.86 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.64
Now: $2.65
$2.89
50-Day Range
$2.50
MA: $2.71
$3.15
52-Week Range
$2.31
Now: $2.65
$7.25
Volume13,904 shs
Average Volume509,933 shs
Market Capitalization$35.56 million
P/E RatioN/A
Dividend YieldN/A
Beta0.98
Hoth Therapeutics, Inc., a development stage biopharmaceutical company, focuses on developing targeted therapeutics for atopic dermatitis. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company was incorporated in 2017 and is based in New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.06 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HOTH
CUSIPN/A
CIKN/A
Phone646-756-2997

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.24 per share

Profitability

Net Income$-7,700,000.00

Miscellaneous

Employees2
Market Cap$35.56 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable
$2.65
-0.29 (-9.86 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HOTH News and Ratings via Email

Sign-up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Hoth Therapeutics (NASDAQ:HOTH) Frequently Asked Questions

How has Hoth Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Hoth Therapeutics' stock was trading at $3.84 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HOTH shares have decreased by 31.0% and is now trading at $2.65.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Hoth Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Hoth Therapeutics
.

When is Hoth Therapeutics' next earnings date?

Hoth Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for Hoth Therapeutics
.

How were Hoth Therapeutics' earnings last quarter?

Hoth Therapeutics Inc (NASDAQ:HOTH) posted its earnings results on Wednesday, May, 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.01.
View Hoth Therapeutics' earnings history
.

What price target have analysts set for HOTH?

1 brokerages have issued 1 year price objectives for Hoth Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Hoth Therapeutics' stock price to reach $10.00 in the next year. This suggests a possible upside of 277.4% from the stock's current price.
View analysts' price targets for Hoth Therapeutics
.

Has Hoth Therapeutics been receiving favorable news coverage?

News stories about HOTH stock have been trending negative on Wednesday, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Hoth Therapeutics earned a news impact score of -2.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.
View the latest news about Hoth Therapeutics
.

Are investors shorting Hoth Therapeutics?

Hoth Therapeutics saw a increase in short interest in February. As of February 15th, there was short interest totaling 25,500 shares, an increase of 99.2% from the January 31st total of 12,800 shares. Based on an average trading volume of 47,200 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.6% of the shares of the stock are short sold.
View Hoth Therapeutics' Short Interest
.

Who are some of Hoth Therapeutics' key competitors?

What other stocks do shareholders of Hoth Therapeutics own?

Who are Hoth Therapeutics' key executives?

Hoth Therapeutics' management team includes the following people:
  • Mr. Robb Knie, Pres, CEO & Director (Age 50)
  • Mr. David S. Briones, Chief Financial Officer (Age 43)
  • Ms. Jane H. Behrmann, VP of Operations (Age 34)

When did Hoth Therapeutics IPO?

(HOTH) raised $8 million in an initial public offering on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO.

What is Hoth Therapeutics' stock symbol?

Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH."

Who are Hoth Therapeutics' major shareholders?

Hoth Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.17%), Magnus Financial Group LLC (0.10%) and Game Plan Financial Advisors LLC (0.08%).
View institutional ownership trends for Hoth Therapeutics
.

Which institutional investors are buying Hoth Therapeutics stock?

HOTH stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., Magnus Financial Group LLC, and Game Plan Financial Advisors LLC.
View insider buying and selling activity for Hoth Therapeutics
.

How do I buy shares of Hoth Therapeutics?

Shares of HOTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Hoth Therapeutics' stock price today?

One share of HOTH stock can currently be purchased for approximately $2.65.

How big of a company is Hoth Therapeutics?

Hoth Therapeutics has a market capitalization of $35.56 million. Hoth Therapeutics employs 2 workers across the globe.

What is Hoth Therapeutics' official website?

The official website for Hoth Therapeutics is www.hoththerapeutics.com.

How can I contact Hoth Therapeutics?

Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company can be reached via phone at 646-756-2997 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.